Barcelona-based
Biorce, a health AI company focused on clinical trial design and execution, has
closed a $52 million Series A round. The financing includes new investment from
DST Global Partners, with existing investors Norrsken VC and YZR Capital increasing
their participation, alongside Mustard Seed Maze. The round also includes angel
investors such as Arthur Mensch, Albert Nieto, Paulo Rosado, and Nik Storonsky.
Following the round, Biorce’s total funding has surpassed $60 million.
Biorce is developing
AI infrastructure to improve how clinical trials are designed and conducted,
with its Aika platform at the core. Aika is an AI-native platform designed to
reduce clinical trial preparation timelines and limit protocol amendments, supporting
faster development of new therapies.
In traditional trial
models, protocol amendments often pause patient recruitment for an average of
six weeks and can add between €500,000 and €1 million in costs per amendment.
These challenges are frequently linked to difficulties in clearly substantiating
trial design decisions to regulatory authorities such as the FDA and the EMA,
which can lead to extended reviews, delays, and additional amendments.
Pedro Coelho, CEO of
Biorce, commented:
Clinical trial delays and inefficiencies cost time, money,
and ultimately lives. Our mission is to make trials faster, more reliable, and
more accessible, so patients can benefit from new treatments sooner.
Built on a dataset of
approximately one million clinical trials, Aika is designed to help anticipate
risks, reduce errors, and limit the need for protocol changes. The platform
supports pharmaceutical companies, biotech firms, and contract research organisations
in designing trials more efficiently while maintaining scientific standards and
patient safety.
Aika is already in use
across multiple therapeutic areas, including oncology, neurology, and rare
diseases. Its therapy-agnostic design allows Biorce to apply AI across a wide
range of clinical programmes and scale its approach to clinical trial design and
management.
Looking ahead, Biorce
plans to expand its workforce and open a development and R&D hub in Austin,
Texas, to support its activities in the US.
In early 2026, the team intends to
further develop Aika’s protocol intelligence capabilities and introduce
additional modules, including tools for contract management, negotiation,
budget planning, and operational execution, aimed at improving trial efficiency
and patient access to new therapies.